Sarepta Therapeutics, Inc. (SRPT) Reports 2-Year Functional Benefit for ELEVIDYS in Older DMD Patients

Sarepta Therapeutics reported that ELEVIDYS showed durable, nominally statistically significant functional benefits over two years vs external controls in ambulatory DMD patients aged 8—12, with manageable safety. Separate data showed robust expression at 12 weeks in 2—3-year-olds.Material DetailsC…